Eli Lilly and Co (LLY)
818.93
-10.81
(-1.30%)
USD |
NYSE |
Nov 01, 16:00
816.48
-2.45
(-0.30%)
After-Hours: 20:00
Eli Lilly Enterprise Value: 805.11B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 805.11B |
| October 31, 2024 | 815.37B |
| October 30, 2024 | 831.59B |
| October 29, 2024 | 885.46B |
| October 28, 2024 | 877.88B |
| October 25, 2024 | 875.14B |
| October 24, 2024 | 829.74B |
| October 23, 2024 | 840.47B |
| October 22, 2024 | 845.78B |
| October 21, 2024 | 843.06B |
| October 18, 2024 | 853.72B |
| October 17, 2024 | 852.95B |
| October 16, 2024 | 852.32B |
| October 15, 2024 | 849.53B |
| October 14, 2024 | 864.10B |
| October 11, 2024 | 866.40B |
| October 10, 2024 | 847.17B |
| October 09, 2024 | 855.31B |
| October 08, 2024 | 849.89B |
| October 07, 2024 | 836.11B |
| October 04, 2024 | 825.99B |
| October 03, 2024 | 824.54B |
| October 02, 2024 | 829.51B |
| October 01, 2024 | 823.58B |
| September 30, 2024 | 824.90B |
| Date | Value |
|---|---|
| September 27, 2024 | 815.99B |
| September 26, 2024 | 844.38B |
| September 25, 2024 | 858.10B |
| September 24, 2024 | 857.98B |
| September 23, 2024 | 852.66B |
| September 20, 2024 | 855.33B |
| September 19, 2024 | 849.53B |
| September 18, 2024 | 840.46B |
| September 17, 2024 | 841.55B |
| September 16, 2024 | 857.18B |
| September 13, 2024 | 857.33B |
| September 12, 2024 | 867.52B |
| September 11, 2024 | 854.79B |
| September 10, 2024 | 837.11B |
| September 09, 2024 | 843.43B |
| September 06, 2024 | 838.42B |
| September 05, 2024 | 847.47B |
| September 04, 2024 | 877.68B |
| September 03, 2024 | 886.89B |
| August 30, 2024 | 890.03B |
| August 29, 2024 | 872.18B |
| August 28, 2024 | 880.05B |
| August 27, 2024 | 885.04B |
| August 26, 2024 | 881.48B |
| August 23, 2024 | 883.47B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
120.47B
Minimum
Nov 05 2019
890.03B
Maximum
Aug 30 2024
362.14B
Average
294.27B
Median
May 04 2022
Enterprise Value Benchmarks
| Amgen Inc | 222.98B |
| Johnson & Johnson | 400.99B |
| Merck & Co Inc | 284.75B |
| Viking Therapeutics Inc | 7.191B |
| Moderna Inc | 12.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 970.30M |
| Revenue (Quarterly) | 11.44B |
| Total Expenses (Quarterly) | 7.005B |
| EPS Diluted (Quarterly) | 1.07 |
| Gross Profit Margin (Quarterly) | 81.02% |
| Profit Margin (Quarterly) | 8.48% |
| Earnings Yield | 1.13% |
| Operating Earnings Yield | 2.04% |
| Normalized Earnings Yield | 1.524 |